FP
PCRX icon

Foundry Partners’s Pacira BioSciences PCRX Stock Holding History

Foundry Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-89,419
Closed -$5.43M – 387
2021
Q2 		$5.43M Sell
89,419
-2,271
-2% -$144K 0.19% 165
2021
Q1 		$6.43M Sell
91,690
-3,153
-3% -$225K 0.21% 147
2020
Q4 		$5.67M Buy
94,843
+741
+0.8% +$43.4K 0.22% 137
2020
Q3 		$5.66M Sell
94,102
-1,426
-1% -$82.9K 0.27% 120
2020
Q2 		$5.01M Buy
+95,528
New +$3.99M 0.24% 133

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Foundry Partners's PCRX Position: Q3 2021 in Review

Foundry Partners sold out of Pacira BioSciences (PCRX) in Q3 2021, closing a stake of 89,419 shares — an estimated $5.43M sold.

Foundry Partners first reported a position in PCRX in Q2 2020 and held it in 5 quarters. The position peaked at $6.43M in Q1 2021. 259 funds tracked by Wall St. Rank hold PCRX as of Q3 2021.

  • Foundry Partners reported no remaining Pacira BioSciences position as of Q3 2021 after selling out during the quarter.
  • Foundry Partners sold 89,419 Pacira BioSciences shares in Q3 2021, an estimated $5.43M.
  • Foundry Partners first reported a position in Pacira BioSciences in Q2 2020 and held it in 5 quarters.
  • Foundry Partners's Pacira BioSciences position peaked at $6.43M in Q1 2021.
  • 259 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2021.

Based on Foundry Partners's 13F filing for Q3 2021, filed 14 Oct 2021.